Vatelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | integrin alpha 2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?)(verify) | |
Vatelizumabis animmunomodulator.It binds tointegrin alpha 2.[1]
It was withdrawn from Phase II trials forinflammatory bowel diseasedue to a lack of efficacy.[2]
References
[edit]- ^World Health Organization(2011)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105"(PDF).WHO Drug Information.25(2).
- ^Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014".Expert Opin Investig Drugs.24(7): 949–56.doi:10.1517/13543784.2015.1035432.PMID25861835.S2CID26104155.
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |